How BayCare’s proton therapy center could change cancer treatment access in West Central Florida

The arrival of the proton accelerator at St. Joseph’s Hospital marks a defining moment for BayCare Health System as it moves closer to offering one of the most advanced forms of cancer treatment available today. The equipment installation is a key milestone in the development of the BayCare Cancer Institute’s proton therapy center in Tampa, a project that began construction just over a year ago. Once operational, the center is expected to provide a new level of precision care for both adult and pediatric cancer patients across West Central Florida, significantly reducing the need for patients to travel to other regions for treatment.

The milestone comes at a time when the demand for precision oncology continues to rise. While traditional radiation therapy remains a critical component of cancer treatment, proton therapy offers a targeted method of delivering radiation that can reduce damage to surrounding healthy tissue. Historically, access to proton therapy has been limited due to the scale, complexity, and cost of the necessary equipment. BayCare’s ability to install a compact, U.S.-manufactured proton accelerator represents both a technological and logistical shift in how this therapy can be deployed in community health systems.

The system was transported from Mevion Medical Systems in Littleton, Massachusetts, and was positioned into place through a detailed operation involving the removal and restoration of concrete roof planks and the use of a 400-ton crane. With the hardware now secured in the custom-built treatment vault, BayCare is progressing toward its target of opening the proton therapy center for patient treatment by mid-2026.

Why is BayCare bringing proton therapy to Tampa now, and how does this reflect broader oncology trends?

Over the last decade, proton therapy has shifted from being considered a highly specialized, limited-availability treatment to a more accessible technology for community healthcare networks. Historically, the infrastructure needed to support proton therapy required large, complex facilities and multi-room configurations, making the treatment more common at national research centers or major academic hospitals than in regional health systems.

BayCare’s move reflects a strategic recognition of changing patient expectations. Cancer patients and their families increasingly seek treatment options closer to home, without the emotional, financial, and physical toll of travel. Proton therapy is often recommended for patients whose tumors are located in areas where collateral radiation damage poses significant long-term risks—such as brain tumors, spinal tumors, and cancers affecting children. For these patients, the potential benefits of proton therapy, including reduced side effects and a lower risk of developing secondary cancers, are significant.

This strategic investment also aligns with a competitive shift in Florida’s healthcare landscape. The Tampa Bay region has emerged as a center for oncology innovation, with multiple health systems expanding their cancer treatment capabilities. By bringing proton therapy into its network, BayCare positions itself at the forefront of patient-centered, technology-driven cancer care and strengthens its ability to attract and retain patients who previously may have sought specialized radiation therapy outside the region.

How does proton therapy work, and why is it considered different from standard radiation treatment?

Proton therapy differs from traditional photon-based radiation therapy in how energy is deposited into tissue. Proton particles carry a positive charge and can be controlled to release radiation doses at a precise depth, creating what is known as the “Bragg Peak.” This allows radiation oncologists to target tumors with exceptional accuracy while sparing surrounding healthy tissue from unnecessary exposure. In contrast, conventional radiation continues to release energy both as it enters and exits the body, impacting more of the surrounding tissue.

The ability to limit radiation exposure offers clear advantages in cases where tumors are located near vital organs or in pediatric patients whose tissues are still developing. Reducing unnecessary radiation minimizes both immediate side effects and long-term complications. For children, in particular, proton therapy may reduce the risk of growth impairment and secondary malignancies later in life.

However, proton therapy is not universally recommended. Treatment teams determine eligibility based on tumor type, location, patient age, medical history, and anticipated therapeutic benefit. The addition of proton therapy to BayCare’s offerings will allow clinicians to consider a broader range of treatment strategies tailored to individual patient needs.

What made it possible for BayCare to accelerate construction and installation?

A key enabler of BayCare’s timeline is the use of a compact proton accelerator system rather than a traditional large-scale cyclotron. Compact systems require less space, less infrastructure reinforcement, and can be integrated more easily into existing hospital campuses. This reduced the construction timeline from what historically could span multiple years into a more efficient building schedule.

The installation itself required careful planning. To place the accelerator, crews removed the roof over the treatment vault, lifted the compact unit into place with a specialized crane, then reinstalled thirty-two concrete planks to restore the structural integrity of the facility. Once sealed, the vault undergoes shielding and calibration procedures to prepare the equipment for clinical testing and regulatory clearance before patient treatments begin.

How will this investment shape cancer care across the Tampa Bay region?

The introduction of proton therapy at St. Joseph’s Hospital has the potential to reshape the care landscape across Central and West Central Florida. Many patients who previously traveled to other regions—sometimes several hours away—will now have a local option. This may lead to earlier treatment starts, better continuity of care, and improved emotional support, as families will be able to remain near home.

For BayCare, this move strengthens its role as a regional leader in oncology and enhances its ability to collaborate across specialties, including surgical oncology, medical oncology, radiation therapy, and supportive care. By integrating proton therapy into a broader care model, BayCare positions itself to deliver more comprehensive and individualized cancer treatment programs.

This development also supports BayCare’s identity as a not-for-profit system prioritizing patient access and equity in advanced care. The organization’s ongoing expansion across ambulatory, pediatric, behavioral health, and home care services suggests that proton therapy is part of a wider strategy to ensure community-level access to high-complexity medical services.

What should patients and clinicians expect as the center moves toward opening in mid-2026?

The next stages will involve clinical staff training, system commissioning, safety testing, quality assurance, and payer engagement to ensure treatment accessibility. Referral pathways will be established both within BayCare’s network and with external providers. Education efforts will also be needed to clarify when proton therapy is clinically indicated versus when conventional radiation or other treatment modalities are more appropriate.

Clinicians are expected to work closely with care teams to identify patient populations that stand to benefit most. Families should expect personalized consultation processes, more detailed pre-treatment planning, and multi-disciplinary collaboration to ensure optimal treatment results.

What are the most important highlights from BayCare’s proton therapy center milestone?

• BayCare Health System has successfully installed the proton accelerator for its new proton therapy center at St. Joseph’s Hospital in Tampa.

• The center is scheduled to begin treating adult and pediatric patients by mid-2026 after testing, calibration, and clinical readiness approvals.

• Proton therapy provides more precise radiation targeting, reducing damage to healthy tissues and potentially lowering long-term treatment side effects.

• The compact Mevion system allowed BayCare to accelerate construction timelines and integrate the accelerator into an existing oncology infrastructure.

• Local access to proton therapy reduces the need for regional patient travel and strengthens BayCare’s position as a leader in comprehensive cancer care in West Central Florida.

• The investment signals BayCare’s long-term strategy to expand high-complexity oncology treatment options within community hospital environments.